https://services.myriad.com/clinical-summaries/gene-pdf.php?gene=CHEK2&allele=1
Guidelines from the National Comprehensive Cancer Network (NCCN) that may apply are listed below.
https://www.ambrygen.com/file/material/view/2681/CMR_UYR_Combo_CHEK2_1125_final.pdf
General population screening for colorectal cancer is appropriate for patients with pathogenic variants in CHEK2.
https://www.ukcgg.org/media/12726/ukcgg_chek2_guideline_version-2_feb-2025.pdf
Studies have reported potential associations of CHEK2GPV with many other cancers including but not limited to renal, thyroid, gastric, pancreatic cancer and haematological malignan
https://www.questdiagnostics.com/content/dam/corporate/documents/qrg/CHEK2.pdf
Blueprint Genetics® offers hereditary cancer testing. To confirm this test result, targeted variant testing for the variant identified is available. You can order a confirmation t
https://www.mskcc.org/pdf/cancer-care/patient-education/about-mutations-chek2-gene
What can I do about my cancer risk if I have a CHEK2 mutation? Your genetic counselor will review your results. They will talk with you about what cancer your mutation is linked to
https://www.labcorp.com/content/dam/genetics/results-guides/Invitae%20-%20CHEK2%20p.Ile157Thr.pdf
GENERAL GUIDELINES POSITIVE RESULTS GUIDE: CHEK2 This document is not part of the Invitae® clini. al report and does not represent medical advice. These are general guidelines tha
https://www.questdiagnostics.com/content/dam/corporate/brochure-pdfs/CHEK2.pdf
There are options for cancer prevention and early detection. The following are general guidelines for individuals who have a CHEK2 pathogenic variant. These guidelines are evolving